NCT06914895

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 905 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

Conditions

• Type 1 Diabetes
• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Tirzepatide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2025-04-25
• Primary completion: 2026-11-01
• Completion: 2026-12-01
• First posted: 2025-04-06
• Last updated: 2026-02-17

Locations

146 sites across 12 countries: United States, Argentina, Brazil, Denmark, France, Germany, Israel, Italy, Japan, Mexico, Puerto Rico, Spain

Regulatory

• FDA-regulated drug study